-

Cyclo Therapeutics to Present at BIOTECH SHOWCASE™ 2020 in San Francisco

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that N. Scott Fine, Chairman and Chief Executive Officer, and other members of the management team will represent the company at Biotech Showcase™ 2020, to be held January 13–15 at the Hilton San Francisco Union Square, 3330 O’Farrell Street, San Francisco, CA 94102.

Cyclo Therapeutics is scheduled to present:

Monday, January 13, 2020,

10:00 a.m. to 10:30 a.m. PST.

Individuals who cannot attend the meeting in person can find webcast information at: www.cyclotherapeutics.com. A replay will also be available following the meeting.

About Cyclo Therapeutics:

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is in three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease (ClinicalTrials.gov NCT02939547, NCT02912793 and NCT03893071), and in an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the company’s website: www.cyclotherapeutics.com

About BIOTECH SHOWCASE:

Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather in San Francisco during this bellwether week which sets the tone for the coming year. Now in its 12th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.

Contacts

RedChip Companies, Inc.
Victor Roberts
407-571-0909
victor@redchip.com

Cyclo Therapeutics, Inc.

OTCQB:CTDH

Release Versions

Contacts

RedChip Companies, Inc.
Victor Roberts
407-571-0909
victor@redchip.com

More News From Cyclo Therapeutics, Inc.

Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with rare and challenging diseases, today announced the presentation of data from its ongoing Pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (“NPC1”) at the 21st Annual WOR...

Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium™ 2025

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced its abstracts have been accepted for oral and poster presentation at the 21st Annual WORLDSymposium™ being held February 3-7, 2025 in San Diego, CA. Details of the presentations are as follows: Oral P...

Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the third quarter 2024 and provided a business update. “The third quarter has been marked by important advancements on our clinical and corporate fronts. We are poised to comp...
Back to Newsroom